Wantai Biotech announced that the nine-valent human papillomavirus vaccine independently developed by Xiamen Wantai Canghai Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, was approved by the Thai Food and Drug Administration, making it the first overseas marketing license for this product. The vaccine obtained a drug registration certificate issued by the State Drug Administration in 2025. It is the first nine-valent HPV vaccine in China and the second nine-valent HPV vaccine in the world. It is suitable for women aged 9-45, covering seven high-risk types of HPV 16/18/31/33/45/52/58 and two low-risk types of HPV6/11.
Zhitongcaijing · 3d ago
Share
Listen to the news
Wantai Biotech announced that the nine-valent human papillomavirus vaccine independently developed by Xiamen Wantai Canghai Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, was approved by the Thai Food and Drug Administration, making it the first overseas marketing license for this product. The vaccine obtained a drug registration certificate issued by the State Drug Administration in 2025. It is the first nine-valent HPV vaccine in China and the second nine-valent HPV vaccine in the world. It is suitable for women aged 9-45, covering seven high-risk types of HPV 16/18/31/33/45/52/58 and two low-risk types of HPV6/11.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending